Latest news for Zedcor (OTC:CRFQF) Stock

Zedcor Inc is engaged in providing security & surveillance services, and rental of surface equipment & accommodations in Western Canada. The company operates in one segment namely, Security & Surveillance. The firm offers three main services to customers across all market segments such as surveillance and live monitoring through its proprietary MobileyeZ security towers; surveillance and live monitoring of fixed site locations; and security personnel.

Zedcor Inc

SuperCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>), a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, announced today that it has secured a new electronic monitoring (EM) contract with a Juvenile Probation Agency in Ohio. This contract marks SuperCom's first project with a government agency in Ohio and its entry into its sixth new U.S. state since the summer of 2024, highlighting SuperCom's expansion momentum in providing innovative public safety solutions nationwide. This contract also marks the 20th new EM contract in the U.S. since the summer of 2024.
&nbsp;
The project in Ohio will include SuperCom's innovative PureOne technology, which provides real-time GPS tracking, secure communication, and advanced compliance capabilities. The discreet PureOne device, designed with a humane approach, helps participants avoid stigma while remaining integrated into society and continuing their rehabilitation journey. These cutting-edge solutions are tailored specifically for correctional and juvenile programs, enhancing public safety while promoting reintegration and operational efficiency.

News

SPCB

SuperCom Expands to Ohio, Secures Juvenile Probation EM Contract with Innovative PureOne Technology

Needham analyst Scott Berg reiterates ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Buy and maintains $125 price target.

Price Target

Reiteration

Analyst Ratings

TTAN

Needham Reiterates Buy on ServiceTitan, Maintains $125 Price Target

<ul>
<li>100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years</li>
<li>100% (9/9) of treated evaluable subjects demonstrated improvement or stabilization in mobility testing, which was only performed up to one year</li>
<li>Improvement in visual function was statistically significant (p=0.01, treated vs untreated eyes), regardless of mutation at two years</li>
<li>Favorable long-term safety and tolerability profile with no serious adverse events related to OCU400</li>
</ul>

OCGN

Ocugen Reveals Two-Year Results From Phase 1/2 Trial Of OCU400, An Innovative Modifier Gene Therapy For Retinitis Pigmentosa

Preliminary Fourth Quarter and Full Year 2024 Financial Results&#x2A; and Recent Business Highlights
<ul>
<li>Preliminary fourth quarter and full-year 2024 U.S. net product revenue for OGSIVEO were $61.5 million and $172.0 million, respectively.</li>
<li>As of December 31, 2024, total preliminary cash, cash equivalents, and marketable securities was $461.9 million. SpringWorks expects its cash position to fund operations through profitability, which the Company anticipates achieving in the first half of 2026.</li>
<li>Presented long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with progressing desmoid tumors in the fourth quarter of 2024. These results showed that longer-term treatment with nirogacestat (median duration of treatment: 34 months) was associated with further reductions in tumor size, increase in objective response rate with additional partial responses and complete responses, sustained improvements in desmoid tumor symptoms including pain, and a consistent safety profile.</li>
<li>Obtained an exclusive, global license from Rappta Therapeutics Oy for a first-in-class molecular glue of specific Protein Phosphatase 2A (PP2A) complexes. PP2A mutations represent a class of targetable oncogenic drivers in molecularly defined subsets of uterine cancer patients with high unmet need. In preclinical models of PP2A mutant uterine cancer, SW-3431 (formerly RPT04402) showed rapid, deep and durable tumor regressions as a monotherapy. In exchange for the license, Rappta received a $13 million upfront payment and is eligible to receive further clinical, regulatory and commercial milestone payments, and tiered single digit royalties on net sales.</li>
</ul>

Earnings

SWTX

SpringWorks Therapeutics Reported Q4 OGSIVEO Revenue Of $61.5M, Cash Balance Of $461.9M

Johnson &amp; Johnson expects to fund the transaction through a combination of cash on hand and debt. Johnson &amp; Johnson expects to maintain a strong balance sheet and to continue to support its stated capital allocation priorities of R&amp;D investment, competitive dividends, value-creating acquisitions, and strategic share repurchases.
Johnson &amp; Johnson will provide commentary on any potential impact to Adjusted Earnings Per Share (EPS) from the transaction when it provides its initial full year 2025 guidance during the fourth quarter earnings call on Wednesday, January 22, 2025.
 &nbsp;

ITCI

Johnson & Johnson Says Intra-Cellular Acquisition Includes CAPLYTA (Lumateperone), The First And Only US FDA-Approved Treatment For Bipolar I And II Depression As An Adjunctive And Monotherapy

WIIM

Intra-Cellular Therapies shares are trading sharply higher after Johnson & Johnson agreed to acquire the company for $132.00 per share in cash.

LULU

Lululemon shares are trading higher after the company raised its Q4 guidance

lululemon athletica inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) today announced that, for the fourth quarter of fiscal 2024, the Company now expects net revenue will be in the range of $3.560 billion to $3.580 billion, representing growth of 11% to 12% compared to the fourth quarter of fiscal 2023, or growth of 6% to 7% excluding the 53rd week of 2024. The previous guidance range was $3.475 billion to $3.510 billion.
Diluted earnings per share are now expected to be in the range of $5.81 to $5.85 for the fourth quarter of fiscal 2024 compared to the Company's previous guidance range of $5.56 to $5.64.
The Company now expects gross margin to increase approximately 30 basis points relative to the fourth quarter of fiscal 2023, compared to its previous guidance of a decrease of 20 to 30 basis points. It now expects deleverage of selling, general, and administrative expenses of 80 to 90 basis points relative to the fourth quarter of fiscal 2023 compared to its previous guidance of deleverage of 90 to 100 basis points. There is no change to the Company's previous guidance for the effective tax rate.

Guidance

Lululemon Athletica Expects Q4 Revenue Of $3.56B-$3.58B (Prior $3.475B-$3.510B) Vs $3.517B Est, EPS Of $5.81-$5.85 (Prior $5.56-$5.64) Vs $5.66 Est

U.S. stock futures declined on Monday following Friday&#8217;s steep fall. Futures of all four major indices fell in premarket trade.
Friday&#8217;s decline followed a strong upmove in yields as the economy added 256,000 jobs in December, much above the economists&#8217; forecast of 165,000 jobs, the strongest since May 2024.
Traders now await the consumer price inflation data this week on Wednesday, which will further clear the case for the Fed to pause the rate cuts.
The 10-year and two-year Treasury notes yielded 4.78% and 4.42%, respectively. The probability of having no change in the interest rates for the upcoming Jan. 31, 2025 decision was at 97.3%, according to CME Group&#8217;s FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.27%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.86%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.38%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.21%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 0.76% to $576.10&nbsp;and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) dropped 1.16% to $501.35, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Wall Street suffered significant losses last week, erasing all gains since the election. This was primarily driven by a robust jobs report, which increased concerns about persistent inflation and further interest rate hikes by the Federal Reserve. The week&#8217;s trading was also impacted by rising geopolitical tensions and increased inflation expectations.
The session witnessed considerable losses among growth equities, particularly those with high valuations and exposure to interest rate sensitivity. This included semiconductor companies such as Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), as well as technology firms like Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>).
The Dow Jones Industrial Average closed 1.63% lower at 41,938.45, down approximately 697 points. The S&amp;P 500 Index fell 1.54% to 5,827.04, while the Nasdaq Composite dipped 1.63% to 19,161.63. Russell 200, on the other hand, fell 2.22% to 2,189.23.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-1.63%</td>
<td>19,161.63</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.54%</td>
<td>5,827.04</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.63%</td>
<td>41,938.45</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-2.22%</td>
<td>2,189.23</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
On <a href="https://www.benzinga.com/25/01/42939374/as-bond-yields-near-the-crucial-5-mark-last-seen-briefly-in-2023-and-global-financial-crisis-this-analyst-says-market-appears-to-be-overreacting">Friday</a>, the U.S. 30-year Treasury yielded 4.950% by the end of the trading session, however, it touched a high of 5.005% intraday. The 10-year Treasury, on the other hand, yielded an intraday high of 4.790% to settle at 4.762% on Friday.
&#8220;It is most likely that the pressure on interest rates is being driven by inflation fears from the soon-to-be-announced tariffs that Trump 2.0 will bring.&#8221; said Louis Navellier, the chairman and founder of Navellier &amp; Associates. &#8220;The market appears to be overreacting,&#8221; he added.
Ed Yardeni and Eric Wallerstein in their note called &#8216;Bond Vigilantes Spoking Stock Jockey&#8217; said, &#8220;If Tuesday&#8217;s CPI inflation rate for December is higher than expected, causing the 10-year Treasury bond yield to revisit 2023&#8217;s high of 5.00%.&#8221;
As the stocks struggled after Friday&#8217;s reports and bond yields&#8217; reaction, Yardeni and Navellier said that this dip was a buying opportunity.
Navellier said that the market could be additionally reacting to the uncertainty on what the Fed may do. Stocks, however, are taking the higher yields to heart, he added, saying &#8220;There&#8217;s no reason to panic.&#8221; as the pullback on higher rates is likely a &#8220;buying opportunity unless earnings disappoint.&#8221;
Yardeni also reiterated its forecast of 7,000 points on the S&amp;P 500 by the end of the year. &#8220;We still believe that the 10-year Treasury bond yield should trade mostly between 4.25% and 4.75% this year. So we think that the selloffs in the stock and bond markets are buying opportunities.&#8221;
Carson Research&#8217;s VP and global macro strategist, Sonu Varghese in a blog post said that it's not useful to read too much into market moves, especially short-term ones.
He argues that the interest rates are higher because the market likely thinks stronger job creation and economy, will put more upward pressure on inflation, which means the Federal Reserve will have to pause on rate cuts. &#8220;Markets are now expecting just one rate cut in 2025 (with a probability of under 25% for a second one) and don't expect it to happen before June,&#8217; he added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
<ul>
<li>On Monday, the data for December&#8217;s monthly U.S. federal budget will be released at 2:00 p.m., ET.</li>
</ul>
<ul>
<li>On Tuesday, NFIB optimism index for December will be released at 6:00 a.m., ET.</li>
</ul>
<ul>
<li>December&#8217;s headline and core producer price index data will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Kansas City Fed President Jeffrey Schmid will be speaking at 10:00 a.m. ET.</li>
</ul>
<ul>
<li>Fed will release its Beige Book at 2:00 p.m., ET.</li>
</ul>
<ul>
<li>New York Fed President Williams will deliver his opening remarks on the policy at 3:05 p.m., ET.</li>
</ul>
<ul>
<li>On Wednesday, the headline and core consumer price index for December and the Empire State manufacturing survey data for January will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li> Richmond Fed President Barkin will speak at 9:00 a.m., ET.</li>
</ul>
<ul>
<li>New York Fed President Williams will speak at 11:00 a.m., ET.</li>
</ul>
<ul>
<li>Chicago Fed President Goolsbee will speak at 12:00 p.m., ET.</li>
</ul>
<ul>
<li>On Thursday, initial jobless claims till Jan. 11 will be released at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>December&#8217;s U.S. retail sales, import price index and Philadelphia Fed manufacturing survey will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Business inventory data for November and the Home builder confidence index for January will be released at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>On Friday, housing starts and building permits data for December will be released at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>The industrial production and capacity utilization for December will be announced at 9:15 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Comtech Telecommunications Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) was up 10.17% in premarket ahead of its earnings before the opening bell. Analysts expect a quarterly loss of 16 cents per share on revenue of $125.53 million.</li>
</ul>
<ul>
<li>WD-40 Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) was up 2.48% after it posted better-than-expected results for its first quarter and reiterated its FY25 guidance on Friday.</li>
</ul>
<ul>
<li>KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) was down 0.76% ahead of its earnings, which is slated to be reported after the market closes. Analysts expect quarterly earnings of $2.45 per share on revenue of $1.99 billion.</li>
</ul>
<ul>
<li>Nordstrom Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) was up 0.12% after the company said that its net sales rose 4.9%, while comparable sales increased 5.8% for the nine-week holiday period ended Jan. 4.</li>
</ul>
<ul>
<li>Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) was down 16.01%, Quantum Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) declined 7.91%, D-Wave Quantum Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) slipped 14.21% and IONQ Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) fell 14.51% in premarket after CNBC&#8217;s Jim Cramer <a href="https://www.benzinga.com/markets/equities/25/01/42890014/jim-cramer-warns-on-quantum-stories-as-stocks-plunge-we-need-you-out-before-the-froth-goes-away">highlighted</a> the speculative nature of nuclear and quantum computing stocks and advised investors to be cautious and realistic about the potential for short-term gains. </li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were higher in the early New York session by 1.76% to hover around $77.08 per barrel.
The gold spot index was down by 0.36% to $2,705.01 per ounce. The Dollar Index was up 0.34% at the 110.02 level.
Asian markets closed lower on Monday as Hong Kong&#8217;s Hang Seng, Japan&#8217;s Nikkei 225, India&#8217;s S&amp;P BSE Sensex, China&#8217;s CSI 300, Australia&#8217;s ASX 200, and South Korea&#8217;s Kospi index declined. European markets were also trading lower.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/42938954/michael-saylors-microstrategy-faces-risk-if-mstrs-0-convertible-bond-lenders-recall-non-recourse-loans-due-to-covenant-breach-heres-what-it-means-for-investors">Michael Saylor&#8217;s MicroStrategy Faces Risk If MSTR&#8217;s 0% Convertible Bond Lenders Recall Non-Recourse Loans Due To Covenant Breach: Here&#8217;s What It Means For Investors </a></li>
</ul>
Image Via Shutterstock

Analyst Color

Equities

Market Summary

Broad U.S. Equity ETFs

Futures

Pre-Market Outlook

Markets

ETFs

General

ABTS

CMTL

IONQ

NVDA

PLTR

QBTS

QUBT

RGTI

WDFC

US Stock Futures Indicate Lower Opening On Monday After Last Week's Steep Fall: Analyst Says It's A 'Buying Opportunity,' But Market May Dip Further If This Happens

Johnson & Johnson Agrees To Acquire Intra-cellular Therapies For $132.00 Per Share In Cash For Total Equity Value Of $14.6B

Large Cap

Health Care

Johnson & Johnson Has Agreed To Acquire Intra-cellular Therapies For $132.00 Per Share In Cash For A Total Equity Value Of Approximately $14.6B

HC Wainwright &amp; Co. analyst Scott Buck reiterates SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) with a Buy and maintains $26 price target.

SOUN

HC Wainwright & Co. Reiterates Buy on SoundHound AI, Maintains $26 Price Target

Citigroup analyst Andrew Kaplowitz reinstates Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) with a Buy and announces $37 price target.

Initiation

Citigroup Reinstates Buy on Symbotic, Announces $37 Price Target

KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) announced today it has been awarded a global agreement by BP International Limited (bp) for engineering, procurement and construction management (EPCM) services.
&nbsp;
Under the terms of the contract, KBR will provide EPCM for onshore, offshore, greenfield and brownfield conventional energy projects and new energy sector projects worldwide for three years, with an option to extend for two additional years. Additionally, KBR provides bp with market-leading licensed technology solutions, demonstrating the depth and versatility of its capabilities.

KBR Secures Global EPCM Contract with BP for Conventional and New Energy Projects

Barclays analyst Saket Kalia downgrades Definitive Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) from Equal-Weight to Underweight and maintains the price target from $4 to $4.

Downgrades

Barclays Downgrades Definitive Healthcare to Underweight, Maintains Price Target to $4

Barclays analyst Brendan Lynch upgrades Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) from Equal-Weight to Overweight and lowers the price target from $117 to $104.

Upgrades

Barclays Upgrades Crown Castle to Overweight, Lowers Price Target to $104

BMO Capital analyst John Kim upgrades Essex Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) from Market Perform to Outperform and lowers the price target from $323 to $310.

BMO Capital Upgrades Essex Property Trust to Outperform, Lowers Price Target to $310

Barclays analyst Brendan Lynch downgrades Terreno Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) from Overweight to Equal-Weight and lowers the price target from $68 to $60.

TRNO

Barclays Downgrades Terreno Realty to Equal-Weight, Lowers Price Target to $60

Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $320 price target.

ALNY

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target

JP Morgan analyst Jeffrey Zekauskas upgrades Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) from Underweight to Neutral and raises the price target from $40 to $50.

JP Morgan Upgrades Nutrien to Neutral, Raises Price Target to $50

Zedcor Inc. GAAP EPS of -C$0.01, revenue of C$5.8M

Donville Kent Asset Management April 2024 Insights

Donville Kent Asset Mgmt. - Zedcor: Profitable And Cheap Stock To Re-Invest At High Rates Of Return

Zedcor Energy GAAP EPS of C$0.02, revenue of C$7.4M

Zedcor Energy reports Q3 results

Donville Kent Asset Management November 2024 Commentary

CNSWF

CPHRF

CRFQF

CTSDF

EHMEF

ETOLF

KSIOF

MDALF

PRLPF

TNTLF

VFORF

VHIBF

Press Releases

Zedcor Inc. Announces Expanded MobileyeZ Service Agreement for a Leading North American Home Improvement Retailer and Strengthens Balance Sheet

TSXV:ZDC

Zedcor

Comments

Zedcor

News

Latest news for Zedcor (OTC:CRFQF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga